$URGN News
Last published 1d ago
- 1d agoURGNGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - UROGEN PHARMA LTDEarnings Call TranscriptsAll right, so welcome to this next Fireside Chat with Eurogen Pharma. It's my great pleasure to welcome Liz Barnett, President and CEO, as well as Chris Dagnon, Chief Financial Officer. Welcome. Thanks for joining us tod
- 1w agoURGNUroGen Pharma Q3 2026 Earnings Call - UROGEN PHARMA LTDEarnings Call TranscriptsThank you for standing by and welcome to EuroGen Pharma's third quarter 2026 earnings conference call. Currently, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and
- 1w agoURGNUroGen Pharma Ltd. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoURGNUroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and HighlightsGlobeNewswireZUSDURI® generated $68.0 million in revenue in the third quarter of 2026, representing 35% quarter-over-quarter growthThe FDA accepted UroGen’s NDA for UGN-103 (next-generation novel mitomycin-based formulation) for
- 1w agoURGNUroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceGlobeNewswirePRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management
- 1w agoURGNUroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder CancerGlobeNewswirePhase 1 clinical trial to evaluate local intravesical administration of UGN-501UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with
- 2w agoURGNUroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial CancerGlobeNewswireFive-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTOResults demonstrate sustained disease control through extended follow-up among
- 2w agoURGNUroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026GlobeNewswirePRINCETON, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
- 3w agoURGNUroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBCGlobeNewswirePRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
- 2mo agoURGNWells Fargo 21st Annual Healthcare Conference - UROGEN PHARMA LTDEarnings Call TranscriptsThanks everyone for being here. My name is Yanan Zhu. I'm one of the biotech analysts here at Wells Fargo. It is my great pleasure to be joined by the management team of Eurogen. With me here are Liz Barrett, CEO, and Ch
- 2mo agoURGNWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - UROGEN PHARMA LTDEarnings Call TranscriptsThanks everyone for being here. My name is Yanan Zhu. I'm one of the biotech analysts here at Wells Fargo. It is my great pleasure to be joined by the management team of Eurogen. With me here are Liz Barrett, CEO, and Ch
- 2mo agoURGNUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
- 2mo agoURGNUroGen Pharma to Present at Upcoming Investor ConferencesGlobeNewswirePRINCETON, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
- 2mo agoURGNIntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology TherapiesPR NewswireIntraGel Therapeutics, developer of next generation long-acting injectables, today announced an equity investment agreement and a strategic Option...
- 2mo agoURGNUroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology PipelineGlobeNewswireCollaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platformAgreement also includes an exclusive option to
- 2mo agoURGNUroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBCGlobeNewswirePRINCETON, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
- 3mo agoURGNUroGen Pharma Q2 2026 Earnings Call - UROGEN PHARMA LTDEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the URGEN Pharma Q2 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question a
- 3mo agoURGNUroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and HighlightsGlobeNewswireZUSDURI® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growthOnce issued, new U.S. patent is expected to provide protection into July 2044 for ZUSDURI and
- 3mo agoURGNUroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026GlobeNewswirePRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
- 3mo agoURGNUroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103GlobeNewswirePRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
- 4mo agoURGNUroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder CancerGlobeNewswireFDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026UGN-501 is a differentiated
- 5mo agoURGNUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
- 5mo agoURGNUroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solutionGlobeNewswireAgreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolioTeva will be granted a non-exclusive license to sell its generic version of JELMYTO
- 5mo agoURGNUroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswirePRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management
- 6mo agoURGNUroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBCGlobeNewswirePRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a
- 6mo agoURGNZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION TrialGlobeNewswire64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three MonthsFirst and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle
- 6mo agoURGNUroGen Pharma to Present at Upcoming Investor ConferencesGlobeNewswirePRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
- 6mo agoURGNUroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and HighlightsGlobeNewswireZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026JELMYTO achieved
- 6mo agoURGNUroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026GlobeNewswirePRINCETON, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
- 7mo agoURGNUroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial CancerGlobeNewswirePRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
- 7mo agoURGNJournal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURIGlobeNewswire72.2% Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months (79.6%) PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
- 8mo agoURGNUroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of RecurrenceGlobeNewswireNational survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50Many respondents report undergoing five or more cystoscopies, with some
- 8mo agoURGNUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
- 8mo agoURGNUroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireCommercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were
- 8mo agoURGNUroGen Announces Refinanced Term Loan Agreement with Pharmakon AdvisorsGlobeNewswireOpportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125 million debt
- 8mo agoURGNZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBCGlobeNewswire• EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb. 27, 2026
- 8mo agoURGNUroGen Pharma to Present at the TD Cowen 46th Annual Health Care ConferenceGlobeNewswirePRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
- 8mo agoURGNUroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026GlobeNewswirePRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
- 9mo agoURGNUroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech SummitGlobeNewswirePRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
- 10mo agoURGNPermanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer TherapyGlobeNewswirePRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
- 11mo agoURGNUroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswirePRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
- 1y agoURGNUroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains MomentumGlobeNewswireReported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the UTOPIA trial ZUSDURI
- 1y agoURGNUroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA TrialGlobeNewswirePRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
- 1y agoURGNUroGen Pharma to Present at Guggenheim Securities Healthcare Innovation ConferenceGlobeNewswirePRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
- 1y agoURGNUroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025GlobeNewswirePRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
- 1y agoURGNCenters for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026GlobeNewswirePRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
- 1y agoURGNZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder CancerGlobeNewswirePRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, today
- 1y agoURGNUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePRINCETON, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
- 1y agoURGNUroGen Pharma to Present at Upcoming Investor ConferencesGlobeNewswirePRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today
- 1y agoURGNUroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts